Differential effects of M2 and M3 muscarinic antagonists on the sleep-wake cycle
- 1 July 1991
- journal article
- sleep and-rhythms
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 2 (7) , 383-385
- https://doi.org/10.1097/00001756-199107000-00007
Abstract
To study the role of muscarinic receptor subtypes in sleep control, methoctramine (25, 50, 75 μg), a highly selective M2 antagonist, was injected intra-cerebro-ventricularly into freely moving rats. Methoctramine induced a dose-dependent increase in desynchronized sleep (DS) latency (from 62.7 ± 10 min following saline to 122.4 ± 13.8 min with the lowest dose) and a 75% decrease in the amount of DS in 6 h recordings. 4DAMP (a M3/M1 selective antagonist) did not significantly change DS latency and percentage time, but it reduced wakefulness (from 38 ± 2.8% following saline to 25.3 ± 3.7% with a dose of 2.5), and increased slow wave sleep. The results suggest that M2 muscarinic receptors play a selective role in DS physiology.Keywords
This publication has 0 references indexed in Scilit: